AEON Biopharma (AEON) AI Stock Analysis

• Market Cap: $803.93K
• Dividend Yield: N/A
• Average Volume (3M): 6.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.93
• Revenue Growth: N/A
• EPS Growth: -261.69%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -17.38
• Shares Outstanding: 1,110,704
• 10 Day Avg. Volume: 8,571,226
• 30 Day Avg. Volume: 6,105,432
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.12
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

AEON Biopharma is under significant financial distress, with negative profitability and cash flow challenges. While technical indicators show some stabilization, the overall bearish trend persists. The lack of profitability and absence of dividends weigh heavily on its valuation. The neutral earnings call impact slightly offsets these negatives but is insufficient to improve the overall outlook.

Positive Factors

Cost Management

R&D expenses declined 50.8% YoY to $4.4M, which were below the estimate, indicating effective cost management.

Regulatory Approval

Aeon finds alignment with the FDA on key biosimilar pathway requirements, boosting confidence in potential regulatory approval.

Negative Factors

Funding Uncertainty

Given the uncertainty in funding, the price target is adjusted to $5 from $6, reflecting potential financial challenges.

Production Dependency

Aeon relies on Daewoong to manufacture ABP-450, and any production issues with Daewoong could adversely impact Aeon.

AEON Biopharma Business Overview & Revenue Model

Company Description

AEON Biopharma (AEON) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutic treatments targeting neurological and gastroenterological disorders. The company is engaged in the research and development of therapeutic applications for botulinum toxin complex, aiming to address unmet medical needs in various indications such as chronic migraine, cervical dystonia, and other related conditions.

How the Company Makes Money

AEON Biopharma makes money primarily through the development and eventual commercialization of its therapeutic products. The company generates revenue by advancing its drug candidates through clinical trials, securing regulatory approvals, and subsequently marketing these drugs to healthcare providers and institutions. Key revenue streams include potential product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies that may provide milestone payments and royalties. AEON's financial success is significantly influenced by the outcomes of its clinical trials and its ability to navigate the regulatory landscape effectively.

AEON Biopharma Financial Statement Overview

Summary

AEON Biopharma's financial health is precarious, marked by consistent losses, deteriorating equity position, and negative cash flows. The company faces significant challenges in achieving profitability and maintaining financial stability, with high risk of continued financial distress.

Income Statement

AEON Biopharma shows a lack of revenue generation with consistent negative EBIT and net income across the years. The absence of revenue growth and profitability highlights challenges in achieving operational efficiency and market penetration.

Balance Sheet

The balance sheet reflects significant financial distress with a negative stockholders' equity, indicating potential insolvency issues. The company's liabilities exceed its assets, suggesting a high-risk financial position.

Cash Flow

Negative free cash flow and operating cash flow indicate ongoing cash burn without revenue generation. The reliance on financing activities for liquidity suggests unsustainable financial operations.

Breakdown
TTM	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	2.52M	3.36M
	Gross Profit
0.00	0.00	0.00	2.52M	3.36M
	EBIT
75.31M	-48.43M	-65.85M	-16.39M	-53.97M
	EBITDA
-22.08M	-48.36M	-7.91M	-22.14M	-50.41M
	Net Income Common Stockholders
39.92M	-52.56M	-55.64M	-32.91M	172.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.75M	9.75M	5.13M	20.17M	111.75M
	Total Assets
10.78M	10.78M	6.44M	21.21M	114.35M
	Total Debt
131.53M	131.53M	86.89M	72.16M	29.95M
	Net Debt
121.79M	121.79M	81.76M	51.99M	23.63M
	Total Liabilities
281.19M	281.19M	230.26M	224.45M	180.22M
	Stockholders Equity
-287.50M	-287.50M	-234.94M	-208.27M	-67.15M
Cash Flow		Free Cash Flow
-19.67M	-35.89M	-28.60M	-9.46M	-46.42M
	Operating Cash Flow
-19.67M	-35.58M	-28.43M	-9.46M	-44.73M
	Investing Cash Flow
0.00	-306.00K	-170.00K	-1.26M	-117.29M
	Financing Cash Flow
15.05M	40.51M	13.56M	24.57M	73.21M

AEON Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.72, below the 50-day MA of 5.68, and below the 200-day MA of 56.48, indicating a bearish trend. The MACD of -2.01 indicates Negative momentum. The RSI at 24.61 is Positive, neither overbought nor oversold. The STOCH value of 42.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.

AEON Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	70 Outperform	$360.83M	21.14	531.78%	―	53.38%	―
Sector *	49 Neutral	$6.94B	0.66	-52.58%	2.47%	22.65%	0.94%
CYTK	45 Neutral	$5.38B	―	435.49%	―	145.34%	3.20%
FATE	42 Neutral	$104.73M	―	-54.21%	―	-78.55%	-0.92%
ORKA	41 Neutral	$462.76M	―	-28.19%	―	―	-48.01%
KPTI	41 Neutral	$54.03M	―	41.08%	―	-0.55%	49.85%
ATRA	25 Underperform	$40.66M	―	1063.61%	―	1404.02%	59.49%
AEON	24 Underperform	$803.93K	―	13.29%	―	―	-261.69%

AEON Biopharma Corporate Events

AEON Biopharma Releases New Investor Presentation

AEON Biopharma, Inc. has recently updated its investor community by releasing a new corporate presentation on its website, which may be leveraged in future discussions by the company’s management. While the presentation includes forward-looking statements, it’s important to note that this information is not considered “filed” under the Securities Exchange Act and is not incorporated by reference into any future filings, unless explicitly stated.